This preclinical study demonstrates that local ADP release and formation at sites of vascular injury contribute significantly to arterial haemostasis by accelerating platelet aggregation.
Answers are grounded in this paper and cite their sources.
ADP inhibition prolongs bleeding in animal arterial models; leaves open translation to human antiplatelet strategies.
The possible involvement of adenosine diphosphate (ADP) in haemostatic platelet aggregation was investigated by determining the duration of primary haemorrhage as standardized bleeding times from punctures of small mesenteric arteries in anaesthetized rats. The bleeding times were highly significantly increased by infusing into the mesenteric arterial blood flowing towards the punctures either the nucleotide-dephosphorylating enzyme apyrase or the ADP-receptor antagonists ATP, adenosine 5'-(beta,gamma-methylene)triphosphonate (AMP-PCP) or 2-methylthioadenosine 5'-(beta,gamma-methylene)triphosphonate (2-MeS-AMP-PCP). The increases in bleeding times could not be accounted for by local vasodilator effects of the agents. It is concluded that the presence of ADP through local release and/or formation at sites of vascular injury contributes significantly to haemostasis, presumably by accelerating platelet aggregation.
No takes yet. Share an insight, caveat, or question.
McClure et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: